Surgical tricuspid valve replacement

Carlo De Vincentiis; Lorenzo Menicanti

doi:10.1007/978-88-470-5400-4_15

Surgical tricuspid valve replacement

Carlo De Vincentiis, Lorenzo Menicanti

IRCCS Policlinico San Donato

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Tricuspid valve replacement is a high-risk treatment associated with suboptimal results. Emergent clinical status at surgery, advanced age, pulmonary hypertension, and NYHA class III/IV have been identified as predictive risk factors for operative mortality. The operative mortality ranges from 12 to 26 %. For the tricuspid valve replacement, using a mechanical or biological prostheses valve remains a controversial subject. There are no real differences in mortality, morbidity, and rate of reintervention by type of prosthesis implanted. The range of survival at 5 years is 60-72 %, and at 10 years, it is from 42 to 65 %. Freedom from reoperation is about 85 % at 10 years, comparable in the two groups of prosthesis used.

Original language	English
Title of host publication	The Tricuspid Valve in Congenital Heart Disease
Publisher	Springer-Verlag Italia s.r.l.
Pages	177-183
Number of pages	7
ISBN (Print)	9788847054004, 8847053994, 9788847053991
DOIs	https://doi.org/10.1007/978-88-470-5400-4_15
Publication status	Published - Feb 1 2014

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1007/978-88-470-5400-4_15

Fingerprint Dive into the research topics of 'Surgical tricuspid valve replacement'. Together they form a unique fingerprint.

Cite this

@inbook{f0ce63aed6f94b03b46e5e822ff4c996,

title = "Surgical tricuspid valve replacement",

abstract = "Tricuspid valve replacement is a high-risk treatment associated with suboptimal results. Emergent clinical status at surgery, advanced age, pulmonary hypertension, and NYHA class III/IV have been identified as predictive risk factors for operative mortality. The operative mortality ranges from 12 to 26 %. For the tricuspid valve replacement, using a mechanical or biological prostheses valve remains a controversial subject. There are no real differences in mortality, morbidity, and rate of reintervention by type of prosthesis implanted. The range of survival at 5 years is 60-72 %, and at 10 years, it is from 42 to 65 %. Freedom from reoperation is about 85 % at 10 years, comparable in the two groups of prosthesis used.",

author = "{De Vincentiis}, Carlo and Lorenzo Menicanti",

year = "2014",

month = feb,

day = "1",

doi = "10.1007/978-88-470-5400-4_15",

language = "English",

isbn = "9788847054004",

pages = "177--183",

booktitle = "The Tricuspid Valve in Congenital Heart Disease",

publisher = "Springer-Verlag Italia s.r.l.",

}

TY - CHAP

T1 - Surgical tricuspid valve replacement

AU - De Vincentiis, Carlo

AU - Menicanti, Lorenzo

PY - 2014/2/1

Y1 - 2014/2/1

N2 - Tricuspid valve replacement is a high-risk treatment associated with suboptimal results. Emergent clinical status at surgery, advanced age, pulmonary hypertension, and NYHA class III/IV have been identified as predictive risk factors for operative mortality. The operative mortality ranges from 12 to 26 %. For the tricuspid valve replacement, using a mechanical or biological prostheses valve remains a controversial subject. There are no real differences in mortality, morbidity, and rate of reintervention by type of prosthesis implanted. The range of survival at 5 years is 60-72 %, and at 10 years, it is from 42 to 65 %. Freedom from reoperation is about 85 % at 10 years, comparable in the two groups of prosthesis used.

AB - Tricuspid valve replacement is a high-risk treatment associated with suboptimal results. Emergent clinical status at surgery, advanced age, pulmonary hypertension, and NYHA class III/IV have been identified as predictive risk factors for operative mortality. The operative mortality ranges from 12 to 26 %. For the tricuspid valve replacement, using a mechanical or biological prostheses valve remains a controversial subject. There are no real differences in mortality, morbidity, and rate of reintervention by type of prosthesis implanted. The range of survival at 5 years is 60-72 %, and at 10 years, it is from 42 to 65 %. Freedom from reoperation is about 85 % at 10 years, comparable in the two groups of prosthesis used.

UR - http://www.scopus.com/inward/record.url?scp=84930920694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930920694&partnerID=8YFLogxK

U2 - 10.1007/978-88-470-5400-4_15

DO - 10.1007/978-88-470-5400-4_15

M3 - Chapter

AN - SCOPUS:84930920694

SN - 9788847054004

SN - 8847053994

SN - 9788847053991

SP - 177

EP - 183

BT - The Tricuspid Valve in Congenital Heart Disease

PB - Springer-Verlag Italia s.r.l.

ER -